Cantor Fitzgerald analyst Brian Cheng maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Tuesday, setting a price target of $85, which is approximately 90.03% above the present share price of $44.73.
Cheng expects Arcturus Therapeutics to post earnings per share (EPS) of -$2.07 for the fourth quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Hold rating of shares in Arcturus Therapeutics, with an average price target of $64.86.
The analysts price targets range from a high of $114 to a low of $27.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2 million and a net profit of -$53.72 million. The company's market cap is $1.18 billion.
According to TipRanks.com, Cantor Fitzgerald analyst Brian Cheng is currently ranked with 1 stars on a 0-5 stars ranking scale, with an average return of -0.4% and a 31.25% success rate.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.